Features

Executives from the European Chemical Industry Council (Cefic), which represents chemical manufacturers in Europe, provide perspectives on key issues: rising energy, production, and transportation costs and the EU’s Green Deal.

A review of the 2022 financial results from the large bio/pharmaceutical companies. Which companies and products are best posed for 2023? DCAT Value Chain Insights provides an inside look on what lies ahead.

Medicines for Europe, which represents generic drug manufacturers in Europe, has proposed a new medicine security contract for Europe as a means to address potential drug shortages in 2023, including ways to assure manufacturing capacity and combat inflationary pressures.

Bayer made a major leadership move this week, announcing that the former head of Roche Pharmaceuticals will join the company in April and take over as CEO and Chairman in June. Does that portend further growth plans in the company’s pharma business?

Pfizer became the first $100-billion company in the industry in 2022 on the strength of its COVID-19 vaccine and COVID-19 drug. Will its record-breaking results hold in 2023, and how will non-COVID products perform? 

DCAT Value Chain Insights provides its Top 10 Watchlist in new drug approvals, including the mix between small molecules & biologics, small & large companies, and blockbuster contenders.

What are key issues impacting bio/pharma manufacturing and supply in 2023? DCAT Value Chain Insights takes an inside look at what is on the industry’s radar.

Global demand & spending for medicines will increase to $1.9 trillion by 2027. COVID-19 vaccines will continue to be a growth driver, but what else is in play?

Economic uncertainty, supply chain, talent management, and risk mitigation were key issues cited by CEOs in PwC’s Global CEO survey, released at the World Economic Forum in Davos, Switzerland. What are key takeaways from a study of 4,400 CEOs?

More coverage of the J.P. Morgan Annual Healthcare Conference in San Francisco earlier this month, where bio/pharma industry executives highlighted their companies’ strategies and key growth initiatives. What are more highlights?